

1. Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandalà M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P.
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014
2. Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, Marchetti P, De Galitiis F, Testori A, Ferrucci PF, Queirolo P, Spagnolo F, Quagliano P, Carnevale Schianca F, Mandalà M, Di Guardo L, Del Vecchio M. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer. 2014
3. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014
4. Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, Antonuzzo A, Cognetti F, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V.
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol. 2014
5. Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M.
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest. 2014
6. Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, Cocorocchio E, Bernengo MG, Guida M, Marconcini R, Merelli B, Parmiani G, Rinaldi G, Aglietta M, Grosso M, Queirolo P.
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res. 2014
7. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA.
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014
8. Ascierto PA, Chiarion-Sileni V, Muggiano A, Mandalà M, Pimpinelli N, Del Vecchio M, Rinaldi G, Simeone E, Queirolo P.

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. [J Chemother. 2014](#)

9. Queirolo P, Marincola F, Spagnolo F.
Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. [Arch Dermatol Res. 2014](#)
10. Gipponi M, Solari N, Giovinazzo D, Queirolo P, Bertoglio S, Villa G, Gualco M, Bleidl D, Cafiero F.
The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma. [Anticancer Res. 2014](#)
11. Sommariva A, Clemente C, Rossi CR.
Standardization and quality control of surgical treatment of cutaneous melanoma: Looking for consensus of the Italian Melanoma Intergroup. [Eur J Surg Oncol. 2014](#)
12. Pasquali S, Mocellin S, Mozzillo N, Maurichi A, Quaglino P, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M, Rossi CR.
Non-sentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study (N=1,538). [J Clin Oncol 2014](#)
13. Rossi CR, Mozzillo N, Maurichi A, Pasquali S, Quaglino P, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M.
Number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis. [Ann Oncol 2014](#)
14. Rossi CR, Mozzillo N, Maurichi A, Pasquali S, Macripò G, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M.
Number of excised lymph nodes as quality assurance measure for lymphadenectomy in melanoma. [JAMA Surg 2014](#)
15. Pasquali S, Montesco MC, Ginanneschi C, Baroni G, Miracco C, Urso C, Mele F, Lombardi AR, Quaglino P, Cattaneo L, Staibano S, Botti G, Visca P, Zannoni M, Soda G, Corti B, Piloni L, Anselmi L, Lissia A, Vannucchi M, Manieli C, Massi D.
Lymphatic and blood vasculature in primary cutaneous melanomas of the scalp and neck. [Head & Neck. 2014](#)
16. Massi D, Montesco MC.
Blood and lymphatic vessel invasion in primary melanoma of the scalp/neck. [Modern Pathology](#)
17. Colombino M, Sini M, Lissia A, De Giorgi V, Stanganelli I, Ayala F, Massi D, Rubino C, Manca A, Paliogiannis P, Rossari S, Magi S, Mazzoni L, Botti G, Capone M, Palla M, Ascierto PA, Cossu A, Palmieri G; Italian Melanoma Intergroup (IMI).
Discrepant alterations in main candidate genes among multiple primary melanomas. [J Transl Med. 2014](#)

18. Banelli B, Morabito A, Laurent S, Piccioli P, Dozin B, Ghio M, Ascierto PA, Monteghirfo S, Marasco A, Ottaviano V, Queirolo P, Romani M, Pistillo MP.
A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer. Hum Immunol. 2014
19. Maurichi A, Miceli R, Camerini T, Mariani L, Patuzzo R, Ruggeri R, Gallino G, Tolomio E, Tragni G, Valeri B, Anichini A, Mortarini R, Moglia D, Pellacani G, Bassoli S, Longo C, Quaglino P, Pimpinelli N, Borgognoni L, Bergamaschi D, Harwood C, Zoras O, Santinami M.
Prediction of survival in patients with thin melanoma: results from a multi-institution study. J Clin Oncol. 2014
20. Moscarella E, Ricci C, Borgognoni L, Bottoni U, Catricalà C, Dika E, Fanti PA, Landi C, Manganoni AM, Pellacani G, Peris K, Pimpinelli N, Quaglino P, Richetta A, Simonetti V, Stanganelli I, Testori A, Zalaudek I, Argenziano G.
Follow-up of cutaneous melanoma patients: A proposal for standardization. G Ital Dermatol Venereol. 2014
21. Sanlorenzo M, Ribero S, Osella-Abate S, Zugna D, Marengo F, Macripò G, Fierro MT, Bernengo MG, Quaglino P.
Prognostic differences across sexes in melanoma patients: what has changed from the past? Melanoma Res. 2014
22. Gangemi R, Amaro A, Gino A, Barisione G, Fabbi M, Pfeffer U, Brizzolara A, Queirolo P, Salvi S, Boccardo S, Gualco M, Spagnolo F, Jager MJ, Mosci C, Rossello A, Ferrini S.
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion. Pigment Cell Melanoma Res. 2014
23. Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fargnoli MC, Ghiorzo P, Bressac-de Paillerets B, Nagore E, Avril MF, Caporaso NE, McMaster ML, Cullen M, Wang Z, Zhang X; NCI DCEG Cancer Sequencing Working Group; NCI DCEG Cancer Genomics Research Laboratory; French Familial Melanoma Study Group, Bruno W, Pastorino L, Queirolo P, Banuls-Roca J, Garcia-Casado Z, Vaysse A, Mohamdi H, Riazalhosseini Y, Foglio M, Jouenne F, Hua X, Hyland PL, Yin J, Vallabhaneni H, Chai W, Minghetti P, Pellegrini C, Ravichandran S, Eggermont A, Lathrop M, Peris K, Scarra GB, Landi G, Savage SA, Sampson JN, He J, Yeager M, Goldin LR, Demenais F, Chanock SJ, Tucker MA, Goldstein AM, Liu Y, Landi MT.
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014 May
24. Rossi CR, Mozzillo N, Maurichi A, Pasquali S, Macripò G, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M.
Number of Excised Lymph Nodes as a Quality Assurance Measure for Lymphadenectomy in Melanoma. JAMA Surg. 2014 May 7
25. Pasquali S, Mocellin S, Mozzillo N, Maurichi A, Quaglino P, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M, Rossi CR.
Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. J Clin Oncol. 2014 Mar 20;32(9):935-41.

26. Rossi CR, Mozzillo N, Maurichi A, Pasquali S, Quaglino P, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M.
The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis. Ann Oncol. 2014 Jan;25(1):240-6.
27. Melanoma Management in Italy.
Meetings from the Italian Melanoma Intergroup, January 2009-December 2010. Dermatology Vol. 226, Suppl. 1, 2013
28. Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J, Brugnara S, Colucci G, Ridolfi R, De Salvo GL; Italian Melanoma Intergroup (IMI).
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer. 2011 Jun 7;104(12):1816-21.
29. Casula M, Budroni M, Cossu A, Ascierto PA, Mozzillo N, Canzanella S, Muggiano A, Palmieri G.
The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients. Ann. Oncol. 2010 21:1379-1380.
30. Casula M, Muggiano A, Cossu A, Budroni M, Caracò C, Ascierto PA, Pagani E, Stanganelli I, Canzanella S, Sini M, Palomba G; Italian Melanoma Intergroup (IMI), Palmieri G.
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer. 2009 Oct 3;9:352
31. Casula M, Alaibac M, Pizzichetta MA, Bono R, Ascierto PA, Stanganelli I, Canzanella S, Palomba G, Zattra E; Italian Melanoma Intergroup (IMI), Palmieri G.
Role of the EGF +61A>G polymorphism in melanoma pathogenesis : an experience on a large series of italian case and controls. BMC Dermatol. 2009 Jul 22;9:7
32. Bruno W, Ghorzo P, Battistuzzi L, Ascierto PA, Barile M, Gargiulo S, Gensini F, Gliori S, Guida M, Lombardo M, Manoukian S, Menin C, Nasti S, Origone P, Pasini B, Pastorino L, Peissel B, Pizzichetta MA, Queirolo P, Rodolfo M, Romanini A, Scaini MC, Testori A, Tibiletti MG, Turchetti D, Leachman SA, Bianchi Scarrà G; IMI, Italian Melanoma Intergroup.
Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol. 2009; 61(5):775-82
33. Ghorzo P, Pastorino L, Pizzichetta MA, Bono R, Queirolo P, Talamini R, Annessi G, Bruno W, Nasti S, Gargiulo S, Battistuzzi L, Sini MC, Palmieri G, Bianchi Scarrà G.
CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. Melanoma Res. 2009 Jun;19(3):142-145
34. Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, Ballardini M, Bichisao E, Ridolfi R; Italian Melanoma Intergroup. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. Melanoma Res. 2009 Apr;19(2):100-5
35. Testori A, De Salvo GL, Montesco MC, Trifirò G, Mocellin S, Landi G, Macripò G, Carcoforo P, Ricotti G, Giudice G, Picciotto F, Donner D, Di Filippo F, Soteldo J, Casara D, Schiavon M, Vecchiato A, Pasquali S, Baldini F, Mazzarol G, Rossi CR; Italian Melanoma Intergroup.

- Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol. 2009 Jul;16(7):2018-27
36. Pisano M, Baldinu P, Sini MC, Ascierto PA, Tanda F, Palmieri G.
Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. Ann. Oncol. 19: 2092-2093, 2008
 37. Pagnanelli G, Bono R, Pizzichetta MA, Talamini R, Ascierto PA, Testori A, Stanganelli I; Italian Melanoma Intergroup (IMI).
Clinical and dermoscopic criteria related to melanoma sentinel lymph node positivity. Anticancer Res. 2007 Jul-Aug;27(4C):2939-44
 38. Pizzichetta MA, Stanganelli I, Bono R, Soyer HP, Magi S, Canzonieri V, Lanzanova G, Annessi G, Massone C, Cerroni L, Talamini R; Italian Melanoma Intergroup (IMI).
Dermoscopic features of difficult melanoma. Dermatol Surg. 2007 Jan;33(1):91-9
 39. Casula M, Colombino M, Satta MP, Cossu A, Lissia A, Budroni M, Simeone E, Calemma R, Loddo C, Caracò C, Mozzillo N, Daponte A, Comella G, Canzanella S, Guida M, Castello G, Ascierto PA, Palmieri G; Italian Melanoma Intergroup.
Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. Eur J Cancer. 2007 Jan;43(1):137-43
 40. Palmieri G, Casula M, Ascierto PA, Tanda F, Cossu A.
Molecular classification of patients with malignant melanoma for new therapeutic strategies. J. Clin. Oncol. 25: e20-21, 2007
 41. Rossi CR, De Salvo GL, Trifirò G, Mocellin S, Landi G, Macripò G, Carcoforo P, Ricotti G, Giudice G, Picciotto F, Donner D, Di Filippo F, Montesco MC, Casara D, Schiavon M, Foletto M, Baldini F, Testori A.
The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1.313 patients with cutaneous melanoma: an italian multicentric study. J Nucl Med. 2006; 47: 234-41
 42. Chiarion-Sileni V, Del Bianco P, Romanini A, Guida M, Paccagnella A, Dalla Palma M, Naglieri E, Ridolfi R, Silvestri B, Michiara M, De Salvo GL.
Tolerability of intensified intravenous interferon alfa2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III trial. BMC Cancer. 2006; 6:44
 43. Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R; Italian Melanoma Intergroup (IMI).
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res. 2006; 16: 317-23
 44. Carta F, Demuro PP, Zanini C, Santona A, Castiglia D, D'Atri S, Ascierto PA, Napolitano M, Cossu A, Tadolini B, Turrini F, Manca A, Sini MC, Palmieri G, Rozzo AC; Italian Melanoma Intergroup.
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res. 2005 Aug;15(4):235-44
 45. Mantelli M, Pastorino L, Ghiorzo P, Barile M, Bruno W, Gargiulo S, Sormani MP, Gliori S, Vecchio S, Ciotti P, Sertoli MR, Queirolo P, Goldstein AM, Bianchi-Scarrà G; Italian Melanoma Intergroup.
Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. Melanoma Res. 2004 Dec;14(6):443-8

46. Ridolfi R, Romanini A, Sileni VC, Michiara M, Guida M, Biasco G, Poletti P, Amaducci L, Leoni M, Ravaioli A.
Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma Res. 2004 Aug;14(4):295-9
47. Casula M, Colombino M, Satta MP, Cossu A, Ascierto PA, Bianchi-Scarra G, Castiglia D, Budroni M, Rozzo C, Manca A, Lissia A, Carboni A, Petretto E, Satriano SM, Botti G, Mantelli M, Ghiorzo P, Stratton MR, Tanda F, Palmieri G; Italian Melanoma Intergroup Study.
BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. J Clin Oncol. 2004 Jan 15;22(2):286-92
48. Chiarion-Sileni V, Del Bianco P, De Salvo GL, Lo Re G, Romanini A, Labianca R, Nortilli R, Corgna E, Dalla Palma M, Lo Presti G, Ridolfi R; Italian Melanoma Intergroup (IMI).
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer. 2003 Jul;39(11):1577-85
49. Ridolfi R, Tanganelli L, Scelzi E, Manente P, Palmeri S, Ravaioli A, Fiammenghi L, Romanini A; Italian Melanoma Intergroup.
Chemotherapy and bio-chemotherapy in patients with advanced melanoma: combination therapy with a nitrosourea. J Chemother. 2003 Apr; 15(2):198-202
50. Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup.
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002 Mar 15;20(6):1600-7
51. Casula M, Ascierto PA, Cossu A, Sini MC, Tore S, Colombino M, Satta MP, Manca A, Rozzo C, Satriano SM, Castello G, Lissia A, Tanda F, Palmieri G.
Mutation analysis of candidate genes in melanoma-prone families: evidence of different pathogenetic mechanisms at chromosome 9P21. Melanoma Res. 2003; 13: 571-9
52. Palmieri G, Ascierto PA, Perrone F, Satriano SMR, Ottaiano A, Daponte A, Napolitano M, Caracò C, Mozzillo N, Melucci MT, Cossu A, Tanda F, Gallo C., Satriano RA, Castello G.
Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J. Clin. Oncol. 2003; 21: 767-773
53. Guida M, Ravaioli A, Sileni VC, Romanini A, Labianca R, Freschi A, Brugnara S, Casamassima A, Lorusso V, Nanni O, Ridolfi R.
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (Italian Melanoma Intergroup) trial. J Transl Med. 2003; 1: 13